The treatment of this disease by Bcl-2 antagonists is inspired by the important role of BCL-2 in B-cell lymphoma pathophysiology.[34] SMBA is Bax protein agonist that inhibits tumor growth by specifically acting on the S184 phosphorylated site of Bax.[35] As a new anticancer drug, Bax protein agonist provides a new strategy for the treatment of malignant tumors expressed by BAX since its naissance.[4,35] The drug has been validated in animal living and has not been tested in humans. This evidence concerns the gene BCL2 and cancer.